Related Experiment Video
Updated: Jan 4, 2026

06:05
A BW Reporter System for Studying Receptor-Ligand Interactions
Published on: January 7, 2019
8.1K
Rituximab as most adequate treatment option for CD20-positive balanitis plasmacellularis Zoon!
Georgi Tchernev1, Ivanka Temelkova1
1Onkoderma-Clinic for Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
Dermatologic Therapy
|October 31, 2019
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
416
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
416
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
432
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
432

